<code id='03B4B4FC2D'></code><style id='03B4B4FC2D'></style>
    • <acronym id='03B4B4FC2D'></acronym>
      <center id='03B4B4FC2D'><center id='03B4B4FC2D'><tfoot id='03B4B4FC2D'></tfoot></center><abbr id='03B4B4FC2D'><dir id='03B4B4FC2D'><tfoot id='03B4B4FC2D'></tfoot><noframes id='03B4B4FC2D'>

    • <optgroup id='03B4B4FC2D'><strike id='03B4B4FC2D'><sup id='03B4B4FC2D'></sup></strike><code id='03B4B4FC2D'></code></optgroup>
        1. <b id='03B4B4FC2D'><label id='03B4B4FC2D'><select id='03B4B4FC2D'><dt id='03B4B4FC2D'><span id='03B4B4FC2D'></span></dt></select></label></b><u id='03B4B4FC2D'></u>
          <i id='03B4B4FC2D'><strike id='03B4B4FC2D'><tt id='03B4B4FC2D'><pre id='03B4B4FC2D'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:leisure time    Page View:81

          Does biotech prepare you for the presidency? Who really wants to gut the FDA? And why do drug companies struggle with IT?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss how Vivek Ramaswamy, fresh off his headline-grabbing debut at the first Republican presidential debate, went from a drug industry entrepreneur to a GOP rising star — and how his former biotech colleagues are reacting to it. We also explain the latest news in the life sciences, including a curious data leak and the family business of a famed biotech inventor.

          advertisement

          For more on what we cover, here’s more on Ramaswamy; here’s the news on the data leak; here’s the story on the latest Langer venture; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          knowledge

          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more
          Biotech stock slump in 2023: awaiting the turnaround
          Biotech stock slump in 2023: awaiting the turnaround

          AdobeThiswassupposedtobetheyearofthebiotechcomeback,whenpromisingnewmedicinesandhigh-dollarbuyoutswo

          read more
          Virginia high school admissions case could be legal follow
          Virginia high school admissions case could be legal follow

          3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

          read more

          FDA panel to weigh approval of NurOwn, controversial ALS drug

          AdobeYearsofpolarizingscientificdiscourseandbruisingonlinedebatewillcometoaheadnextweekwhenadviserst